nach oben

Erschienen in:

2023 | OriginalPaper | Buchkapitel

6. Arterielle Hypertonie

verfasst von : Prof. Dr. med. Thomas Eschenhagen, Prof. Dr. med. Joachim Weil

Erschienen in: Arzneiverordnungs-Report 2023

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf einen Blick

In diesem Kapitel werden die Antihypertonika gemeinsam auf der Basis der aktuellen Empfehlungen zur antihypertensiven Therapie dargestellt. Damit werden die früher getrennten Kapitel zu Hemmstoffen des Renin-Angiotensin Systems, Calciumkanalblockern, β-Adrenozeptor-Antagonisten (Betablocker) sowie speziellen Antihypertonika wie α-Adrenozeptor-Antagonisten und zentral wirkenden Antisympathotonika zusammengeführt. Dies trägt der Tatsache Rechnung, dass es sich bei der antihypertensiven Therapie um eine in alle Bereiche der kardiovaskulären Medizin reichende Basistherapie handelt, die einen integrierten Ansatz erfordert. Die als Antihypertonika ebenfalls wichtigen Diuretika und Aldosteronrezeptorantagonisten werden gesondert in Kap. 34 besprochen. Zusätzlich wird auf unvermeidbare Überschneidungen mit den Kardiaka in Kap. 7 verwiesen.

Ablad B, Bjurö T, Björkman JA, Edström T (2007) Prevention of ventricular fibrillation requires central beta-adrenoceptor blockade in rabbits. Scand Cardiovasc J 41:221–229PubMedCrossRef

Agarwal R (2017) Implications of blood pressure measurement technique for implementation of systolic blood pressure intervention trial (SPRINT). J Am Heart Assoc 6:e4536. https://doi.org/10.1161/JAHA.116.004536 CrossRef

Anlauf M, Weber F (2018) Blutdruckmessungen zur Hochdruckbekämpfung sollten i. d. R. mit Automaten erfolgen. Dtsch Med Wochenschr 143:59–60PubMedCrossRef

Arzneimittelkommission der Deutschen Ärzteschaft (2019) Hydrochlorothiazid: Risiko von nichtmelanozytärem Hautkrebs – Empfehlungen der AkdÄ zur Behandlung von Hypertonie und Herzinsuffizienz. Arzneiverordn Prax 46:1–2

Azizi M, Rossignol P, Hulot JS (2019) Emerging drug classes and their potential use in hypertension. Hypertension 74:1075–1083PubMedCrossRef

Bakris G, Ali W, Parati G (2019) ACC/AHA versus ESC/ESH on hypertension guidelines: JACC guideline comparison. J Am Coll Cardiol 73:3018–3026PubMedCrossRef

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181PubMedCrossRef

Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH (2017) Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 356:j4. https://doi.org/10.1136/bmj.j4 CrossRefPubMedPubMedCentral

Barnes H, Brown Z, Burns A, Williams T (2019) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012621.pub2 CrossRefPubMedPubMedCentral

Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013) Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168:3572–3579PubMedPubMedCentralCrossRef

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898PubMedCrossRef

Berrido AM, Byrd JB (2020) Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls. Curr Hypertens Rep 22:20PubMedCrossRef

BPLTTC The Blood Pressure Lowering Treatment Trialists’ Collaboration (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397:1625–1636CrossRef

British Hypertension Society Studies Group, Williams B, MacDonald TM, Morant S, Webb DJ, Sever P et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068CrossRef

British Hypertension Society’s Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group, Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ et al (2016) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 4:136–147CrossRef

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2014) Nationale Versorgungsleitlinie Chronische KHK. Langfassung, 3. Auflage, Version 1, Dezember 2014, AWMF-Register-Nr.: nvl-004. http://www.leitlinien.de/nvl/khk/

Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, Qamar A et al (2020) Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother 6:356–363PubMedCrossRef

Canadian Hypertension Canadian hypertension. https://guidelines.hypertension.ca/prevention-treatment/uncomplicated-hypertension-goals-of-therapy/. Zugegriffen: 23. Mai 2020

Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S et al (2021) Comparative first-line effectiveness and safety of ACE (Angiotensin-Converting Enzyme) inhibitors and Angiotensin receptor blockers: a multinational cohort study. Hypertension 78:591–603PubMedCrossRef

Chow CK, Thakkar Z, Bennett A, Hillis G, Burke M et al (2017) Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet 389:1035–1042PubMedCrossRef

CIBIS II Study (1999) The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353:9–13CrossRef

Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group (1995) Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII. Circulation 92:1–143

COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, Chen ZM, Pan HC, Chen YP, Peto R, Collins R et al (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1622–1632CrossRef

Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T et al (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29:4–16PubMedCrossRef

Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895–906PubMedCrossRef

Danesh AH, Gottschalk PCH (2019) Beta-blockers for migraine prevention: a review article. Curr Treat Options Neurol 21:20PubMedCrossRef

Daniel WJ, Whelton PK, Allen N, Clark D III, Gidding SS et al (2021) Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap. A scientific statement from the American Heart Association. Hypertension 77:e58–e67

Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J et al (2019) Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 64:1–9PubMedCrossRef

Dondo TB, Hall M, West RM, Jernberg T, Lindahl B et al (2017) β-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol 69:2710–2720PubMedPubMedCentralCrossRef

Easterling T, Mundle S, Bracken H, Parvekar S, Mool S et al (2019) Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet 394:1011–1021PubMedPubMedCentralCrossRef

Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y et al (2012) Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59:1124–1131PubMedCrossRef

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207PubMedCrossRef

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967PubMedCrossRef

Falaschetti E, Mindell J, Knott C, Poulter N (2014) Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383:1912–1919PubMedCrossRef

FDA Drug Safety Communication (2013) FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-include-intestinal-problems-sprue

Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R et al (2013) Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310:2544–2553PubMedCrossRef

Gomm W, Röthlein C, Schüssel K, Brückner G, Schröder H et al (2021) N-nitrosodimethylamine-contaminated valsartan and the risk of cancer – A longitudinal cohort study based on German health insurance data. Dtsch Ärztebl Int 118:357–362PubMedPubMedCentral

Gulea C, Zakeri R, Alderman V, Morgan A, Ross J et al (2021) Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Resp Res 22:64CrossRef

Hänggi D, Etminan N, Aldrich F, Steiger HJ, Mayer SA, NEWTON Investigators (2017) Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke 48:145–151PubMedCrossRef

Hausberg M, Trenkwalder P, Weisser B, Krämer BK (2019) Antihypertensiva: Verunsicherung durch potenziell gravierende Nebenwirkungen. Dtsch Ärztebl 116:A366–A370

Heerspink HL, de Zeeuw D (2010) Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375:1140–1142PubMedCrossRef

Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S et al (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31:2888–2896PubMedCrossRef

Herrett E, Gadd S, Jackson R, Bhaskaran K et al (2019) Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study. Lancet 394(10199):663–671PubMedPubMedCentralCrossRef

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA et al (2018) Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 363:k4209PubMedPubMedCentralCrossRef

Ho JK, Moriarty F, Manly JJ, Larson EB, Evans DA et al (2021) Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly. A meta-analysis. Hypertension. https://doi.org/10.1161/HYPERTENSIONAHA.121.17049 CrossRefPubMed

Holt A, Blanche P, Zareini B, Rajan D, El-Sheikh M et al (2021) Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J 42:907–914PubMedCrossRef

Hopkins W, Rubin LJ (2021) Treatment of pulmonary arterial hypertension (group 1) in adults: pulmonary hypertension-specific therapy. https://www.uptodate.com/contents/treatment-of-pulmonary-arterial-hypertension-group-1-in-adults-pulmonary-hypertension-specific-therapy?source=history_widget

Huang Y, Su L, Cai X, Mai W, Wang S et al (2014) Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167:160–168PubMedCrossRef

Hermida RC, Crespo JJ, Domínguez-Sardiña M, Otero A, Moyá A et al (2019) Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia chronotherapy trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz754 CrossRefPubMed

HYVET Study Group, Beckett N, Peters R, Tuomilehto J, Swift C, Sever P et al (2011) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:d7541CrossRef

Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, Taylor AA, Hau C, Klint A, Huang GD, Brophy MT, Fiore LD, Ferguson RE (2022) Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med 387(26):2401–2410. https://doi.org/10.1056/NEJMoa2212270 CrossRefPubMed

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K et al (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359:2417–2428PubMedCrossRef

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031PubMedCrossRef

Khan NA, Rabkin SW, Zhao Y et al (2018) Effect of lowering diastolic pressure in patients with and without cardiovascular disease: analysis of the SPRINT (systolic blood pressure intervention trial). Hypertension 71:840–847PubMedCrossRef

Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R et al (2014) Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230CrossRef

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477PubMedCrossRef

Krieger EM, Drager LF, Giorgi DMA et al (2018) Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 71:681–690PubMedCrossRef

Kunz R, Friedrich C, Wolbers M, Mann JFE (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMedCrossRef

Lawlor B, Segurado R, Kennelly S, Rikkert OMGM, Howard R, NILVAD Study Group et al (2018) Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial. PLoS Med 15:e1002660PubMedPubMedCentralCrossRef

Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD et al (2020) Association between Angiotensin-converting enzyme inhibitors and lung cancer – A nationwide, population-based, propensity score-matched cohort study. Cancers 12(3):747. https://doi.org/10.3390/cancers12030747 CrossRefPubMedPubMedCentral

Lindholm LH, Carlberg B, Samuelsson O (2005) Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553PubMedCrossRef

Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L et al (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009–2020PubMedCrossRef

Lopes RD, Macedo AVS, de Barros E, Silva PGM, Moll-Bernardes RJ et al (2021) Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325(3):254–264PubMedPubMedCentralCrossRef

Lüders S, Schrader J, Berger J, Unger T, Zidek W et al (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – A prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487–1496PubMedCrossRef

Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M et al (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185:949–957PubMedPubMedCentralCrossRef

Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ et al (2022) Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 400:1417–1425PubMedPubMedCentralCrossRef

Mahfoud F, Kieble M, Enners S, Werning J, Laufs U et al (2020a) „Dear Doctor“ warning letter (Rote-Hand-Brief) on hydrochlorothiazide and its impact on antihypertensive prescription. Dtsch Ärztebl Int 117:687–688PubMedPubMedCentral

Mahfoud F, Aziz M, Ewen S, Pathak A et al (2020b) Proceedings from the 3rd European clinical consensus conference for clinical trials in device-based hypertension therapies. Eur Heart J 41:1588–1599PubMedPubMedCentralCrossRef

Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (2009) Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 31:1652–1663PubMedCrossRef

Mancia G, Corrao G (2018) Global impact of the 2017 American College of Cardiology/American heart association hypertension guidelines: a perspective from Italy. Circulation 137:889–890PubMedCrossRef

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G et al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 41:1874–2071PubMedCrossRef

Masoli JAH, Delgado J, Pilling L, Strain D, Melzer D (2020) Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing 49:807–813PubMedPubMedCentralCrossRef

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV et al (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374:1521–1532PubMedCrossRef

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004PubMedCrossRef

MERIT-HF Study (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353:2001–2007CrossRef

Middeke M, Lemmer B, Kreutz R, Schrader J, Holzgreve H (2020) Antihypertensiva nicht generell abends nehmen. MMW Fortschr Med 162:34–36PubMedCrossRef

van Middelaar T, van Vught LA, van Charante EPM, Eurelings LSM, Ligthart SA et al (2017) Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens 35:2095–2101PubMedCrossRef

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM et al (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134:441–450PubMedPubMedCentralCrossRef

Morgan T, Lauri J, Bertram D, Anderson A (2004) Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 17:118–123PubMedCrossRef

MOXCON Investigators, Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K et al (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5:659–667CrossRef

Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J et al (2014) Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens 16:323–330CrossRef

NCD Risk Factor Collaboration (NCD-RisC) (2019) Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 394(10199):639–651CrossRef

Neuhauser H, Diederichs C, Boeing H, Felix SB, Jünger C et al (2016) Bluthochdruck in Deutschland – Daten aus sieben bevölkerungsbasierten epidemiologischen Studien (1994–2012). Dtsch Ärztebl Int 113:809–815PubMedPubMedCentral

NICE, National Institute for Health and Care Excellence (2019) Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#starting-antihypertensive-drug-treatment. Zugegriffen: 23. Mai 2020

Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B et al (2013) Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310:1135–1144PubMedCrossRef

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M et al (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292:2217–2225PubMedCrossRef

Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB et al (2018) Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 24:1108–1112PubMedPubMedCentralCrossRef

Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE et al (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107–1114PubMedCrossRef

Packer M, Coats AJS, Fowler MB, Katus HA et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRef

Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV et al (2016) Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 67:379–389PubMedCrossRef

Pickard R, Starr K, MacLennan G, Lam T, Thomas R et al (2015) Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet 386:341–349PubMedCrossRef

Pitt B (2004) ACE inhibitors for patients with vascular disease without left ventricular dysfunction – may they rest in PEACE? N Engl J Med 351:2115–2117PubMedCrossRef

Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS et al (2014) TOPCAT Investogators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392PubMedCrossRef

Poulter NR, Savopoulos C, Anjum A, Apostolopoulou M et al (2018) Randomized crossover trial of the impact of morning or evening dosing of antihypertensive agents on 24-hour ambulatory blood pressure. Hypertension 72(4):870–873PubMedCrossRef

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818PubMedCrossRef

Qiao Y, Shin JI, Teresa K, Chen TK, Inker LA et al (2020) Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with lowestimated glomerular filtration rate. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0193 CrossRefPubMedPubMedCentral

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD et al (2014) Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 383:1899–1911PubMedPubMedCentralCrossRef

Rothwell PM, Howard SC, Dolan E, O’Brian E, Dobson JE, ASCOT-BPLA MRC Trial Investigators et al (2010) Effects of β blockers and calcium channel blockers on within-individual variability and risk of stroke. Lancet Neurol 9:469–480PubMedCrossRef

Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59:1110–1117PubMedCrossRef

Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF et al (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87:732–738PubMedPubMedCentralCrossRef

Sackner-Bernstein J (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28(11 Suppl 1):19–27

Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A (2019) Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1567–1573PubMedCrossRef

Sato A, Fukuda S (2015) A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens 37:563–568PubMedCrossRef

Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE et al (2010) Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307PubMedCrossRef

Sexton DJ, Canney M, O’Connell MDL, Moore P, Little MA et al (2017) Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med 177:1385–1387PubMedPubMedCentralCrossRef

SHEP Collaborative Research Group, Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL et al (2005) Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95:29–35CrossRef

Sheppard JP, Stevens S, Stevens R, Martin U, Mant J et al (2018) Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 178:1626–1634PubMedPubMedCentralCrossRef

Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ (2014) Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 64:588–597PubMedPubMedCentralCrossRef

Smith L, Parris C, Veronese N, Shang C, Lopez-Sanchez GF et al (2020) Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med. https://doi.org/10.1007/s10238-020-00622-7 CrossRefPubMed

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP et al (2019) PARAGON-HF investigators and committees angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620PubMedCrossRef

SPRINT Research Group, Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: A randomized clinical trial. JAMA 315:2673–2682CrossRef

SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC (2021) Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384:1921–1930

Stergiou GS, Palatini P, Parati G, O’Brien E et al (2021) 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 39:1293–1302PubMedCrossRef

Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R et al (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 394:1816–1826PubMedPubMedCentralCrossRef

Sun H, Hodgkinson CP, Pratt RE, Dzau VJ (2021) CRISPR/Cas9 mediated deletion of the angiotensinogen gene reduces hypertension: a potential for cure? Hypertension 77:1990–2000PubMedCrossRef

Svensson P, de Faire U, Sleight P, Yusuf S, Östergren JJ (2001) Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32PubMedCrossRef

The ACTIVE I Investigators (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938CrossRef

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981–2997CrossRef

The Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964CrossRef

The Blood Pressure Lowering Treatment Trialists’ Collaboration (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397(10285):1625–1636CrossRef

The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788CrossRef

The GISSI-AF Investigators (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617CrossRef

The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153CrossRef

The ONTARGET Investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRef

The SPRINT Research Group (2015) A randomized trial of intensive versus standard blood pressure control. N Engl J Med 373:2103–2116PubMedCentralCrossRef

Thomopoulos C, Parati G, Zanchetti A (2017a) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2138–2149PubMedCrossRef

Thomopoulos C, Parati G, Zanchetti A (2017b) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944PubMedCrossRef

Thomopoulos C, Parati G, Zanchetti A (2017c) Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2150–2160PubMedCrossRef

Thomopoulos C, Parati G, Zanchetti A (2018) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 – effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens 36:1637–1647PubMedCrossRef

Trafford JA, Latta D, Little PS, Parsley J, Ankier SI et al (1989) A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. Curr Med Res Opin 11:550–556PubMedCrossRef

Trump S, Lukassen S, Anker MS, Chua RL, Liebig J et al (2020) Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol 39:705–716PubMedCrossRef

Uijl E, Mirabito Colafella KM, Sun Y, Ren L et al (2019) Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen. Hypertension 73:1249–1257PubMedCrossRef

Van Noord T, Tieleman RG, Bosker HA, Kingma T, van Veldhuisen DJ et al (2004) Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 6:343–350PubMedCrossRef

Vargas F, Mendez H (1999) Study of the photochemical and in vitro phototoxicity of chlortalidone [2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzene sulfonamide. Pharmazie 54:920–922PubMed

Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R et al (2004) Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43:963–969PubMedCrossRef

van Vliet E, Nijman T, Schuit E, Heida KY, Opmeer BC et al (2016) Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet 387:2117–2124PubMedCrossRef

Wang CY, Huang KC, Lu CW, Chu CH, Huang CN et al (2022) A randomized controlled trial of R-form Verapamil added to ongoing Metformin therapy in patients with type 2 diabetes. J Clin Endocrinol Metab 107:e4063–e4071PubMedPubMedCentralCrossRef

Weber F, Anlauf M (2014) Treatment resistant hypertension – Investigation and conservative management. Dtsch Ärztebl Int 111:425–431PubMedPubMedCentral

Weisser B, Predel HG, Gillessen A, Hacke C et al (2020) Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. High Blood Press Cardiovasc Prev 27(2):157–164PubMedPubMedCentralCrossRef

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71:e13–e115PubMed

Wikstrand J, Wedel H, Castagno D, McMurray JJV (2013) The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 275:134–143PubMedCrossRef

Williams B, Mancia G, Spiering W, Rosei EA et al (2018) 2018 ESC/ESHGuidelines for the management of arterial hypertension. J Hypertens 36:1953–2041PubMedCrossRef

Wolf PS, Smith RD, Khandwala A, Van Inwegen RG, Gordon RJ et al (1985) Celiprolol – Pharmacological profile of an unconventional beta-blocker. Br J Clin Pract Suppl 40:5–11PubMed

Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S et al (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43:10–17PubMedCrossRef

Wong GWK, Boyda HN, Wright JM (2014) Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007450.pub2 CrossRefPubMedPubMedCentral

Yang R, Luo Z, Liu Y, Sun M, Zheng L et al (2016) Drug interactions with angiotensin receptor blockers: role of human cytochromes P450. Curr Drug Metab 17:681–691PubMedCrossRef

Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS et al (2015) Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol 65:327–335PubMedPubMedCentralCrossRef

Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237PubMedPubMedCentralCrossRef

Zhang Y, Sun N, Jiang X, Xi Y (2017) Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis. J Am Soc 11:394–401

Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP et al (1999) Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522–1530PubMedPubMedCentralCrossRef

Titel: Arterielle Hypertonie
verfasst von: Prof. Dr. med. Thomas Eschenhagen
Prof. Dr. med. Joachim Weil
Verlag: Springer Berlin Heidelberg
Buch: Arzneiverordnungs-Report 2023
Print ISBN: 978-3-662-68370-5

Electronic ISBN: 978-3-662-68371-2

Copyright-Jahr: 2023
DOI: https://doi.org/10.1007/978-3-662-68371-2_6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen